Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors

PTT‑4256 is an emerging first‑in‑class small‑molecule inhibitor of GPR65, a proton‑sensing G‑protein‑coupled receptor selectively expressed on immune cells within the acidic tumour microenvironment. It is being evaluated in the RAISIC‑1 trial, a modular, open‑label, phase 1/2 study in patients with advanced solid tumours designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy. The trial’s Module A employs an accelerated dose titration/BOIN design to define the maximum tolerated dose, optimal biological dose, and recommended phase 2 dose of PTT‑4256 monotherapy across a broad solid‑tumour population, including patients with castration‑resistant prostate cancer among other eligible indications.

Preclinically, GPR65 acts like an acid‑sensing immune checkpoint: when the tumour environment becomes more acidic, GPR65 switches on and weakens T‑cell and NK‑cell activity while pushing tumour‑associated macrophages toward an immunosuppressive state. This acidic niche is created naturally by tumour metabolism (glycolysis) and low oxygen, so GPR65 activation helps the cancer hide from immune attack. PTT‑4256 blocks GPR65, effectively taking the brakes off immune cells; in mouse models this boosts pro‑inflammatory signals, increases cytotoxic lymphocyte infiltration, and suppresses immunosuppressive cues, leading to slower tumour growth and better immune control. Instead of directly killing tumour cells, PTT‑4256 works by “normalizing” the tumour microenvironment.

From a human‑data perspective, GPR65 is statistically significant. People who carry a naturally occurring loss‑of‑function variant in GPR65 tend to live longer across several solid‑tumour types, even in cancers that usually resist classic immune checkpoint inhibitors, suggesting that quieting GPR65 strengthens anti‑tumour immunity. Large‑scale analyses across cancers also tie GPR65 expression to immune cell makeup, checkpoint profiles, and overall prognosis, lifting it to the status of a novel immune biomarker and promising therapeutic target. This genetic evidence is exactly what motivates the PTT‑4256 strategy: to mimic, with a drug, the more favourable immune profile already seen in people whose GPR65 activity is naturally reduced.

In the clinic, RAISIC‑1 begins with a wide solid‑tumour pool, allowing the identification of safe and biologically active doses before focusing on specific histologies or combination regimens. For prostate cancer, the relevance of GPR65 lies in the context of an immunologically cold, acidic, and often myeloid‑rich microenvironment characteristic of advanced castration‑resistant disease and bone‑metastatic niches. By targeting a receptor that is upregulated in response to low pH and expressed on tumour‑infiltrating lymphocytes and macrophages, PTT‑4256 offers a mechanistic rationale for re‑arming immune cells in a setting where conventional immunotherapies have largely underperformed.

Clinical trial.